Company Description

BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease.

It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis.

The company’s product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials.

BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.

BiomX Inc.

Country	Israel
Founded	2015
Industry	Biotechnology
Sector	Healthcare
Employees	71
CEO	Jonathan Solomon

Contact Details

Address: 22 Einstein Street, Floor 4 Ness Ziona, 7414003 Israel
Phone	972 7 2394 2377
Website	biomx.com

Stock Details

Ticker Symbol	PHGE
Exchange	NYSEAMERICAN
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001739174
CUSIP Number	09090D103
ISIN Number	US09090D1037
Employer ID	82-3364020
SIC Code	2836

Key Executives

Name	Position
Jonathan Eitan Solomon MBA	Chief Executive Officer and Director
Marina Wolfson CPA	Chief Financial Officer and Secretary
Dr. Merav Bassan Ph.D.	Chief Development Officer
Prof. Rotem Sorek Ph.D.	Scientific Founder
Dr. Eran Elinav M.D., Ph.D.	Scientific Founder
Dr. Timothy K. Lu M.D., Ph.D.	Scientific Founder
Inbal Benjamini-Elran	C.H.R.O

Latest SEC Filings

Date	Type	Title
Feb 27, 2025	8-K	Current Report
Feb 27, 2025	424B5	Filing
Feb 27, 2025	424B3	Prospectus
Feb 24, 2025	424B5	Filing
Feb 14, 2025	SCHEDULE 13G/A	Filing
Dec 16, 2024	8-K	Current Report
Nov 14, 2024	10-Q	Quarterly Report
Nov 14, 2024	8-K	Current Report
Nov 13, 2024	SCHEDULE 13G	Filing
Nov 13, 2024	SC 13G/A	[Amend] Statement of acquisition of beneficial ownership by individuals

View All SEC Filings